Clinical trials on T-ALL patients are ongoing to test the combination of dexamethasone and different AKT inhibitors, leading the way to further prospective use of zebrafish leukemia models in translational approaches (Figure 1A). The gene discussed is AKT1; the disease is acute lymphoblastic leukemia.